The Ledger

Johnson & Johnson booked its proposed $5.5 billion talc settlement in the third quarter, and net earnings fell 95.9% to $210 million from $5.15 billion a year earlier. The company’s third quarter 8-K earnings release shows adjusted earnings of $2.59 per share against $2.80, and reported earnings of $0.09 per share against $2.12, which it ties to “a one-time special charge for the proposed talc litigation resolution” plus the Firefly Bio acquisition and the Sail Biomedicines collaboration. Worldwide sales rose 5.9% to $25.4 billion. J&J still raised its 2026 adjusted earnings outlook to $11.05 to $11.15 per share, up from $10.96 to $11.11 in July. The settlement terms come from J&J’s July 27 announcement: a $5.5 billion commitment covering about 76,000 remaining ovarian talc claims, conditioned on lead plaintiff firms representing at least 95% of those claims joining, with a first payment of no more than $3 billion in 2027 and nothing more due before 2028. No sign-up deadline is stated. The earnings release does not break out the talc charge in the sections we reviewed, so the dollar amount booked in the quarter is not confirmed here. Who it hits: mass-tort defendants and their insurers, and every large health-products maker that carries litigation reserves, since a company can report a near-zero quarter and a higher forecast at the same time. Confidence: High on reported results and settlement terms; Low on whether the 95% threshold is met.

J&J’s device unit grew 2.5% to $8.6 billion in the third quarter, and management said that is below its own standard. The 8-K credits electrophysiology products and Shockwave in cardiovascular, contact lenses, and trauma. Per the earnings call transcript, a supplemental source, U.S. MedTech grew 4.8% and sales outside the U.S. grew 0.1%, the Middle East conflict is disrupting ordering and tender timing, and the company is “on track” to separate its DePuy Synthes orthopaedics business by mid-2027, leaning toward a spin-off. The same transcript puts the segment margin at 22.9% against 21%, helped by tariff recoveries, and says the OTTAVA soft-tissue surgical robot, authorized by the U.S. Food and Drug Administration (FDA) in July, has signed its first commercial customer, with more detail due at a December 8 business review. For hospitals buying orthopaedic implants and robots, the question is who the contracting counterparty is after mid-2027. Confidence: High on the reported 2.5%; Medium on the call details, which rest on a transcript.

Zocdoc, the online doctor-booking marketplace, made its first acquisition in nearly 20 years, buying insurance-eligibility software company Sohar Health. In a PR Newswire release dated October 14, Zocdoc says the deal closed October 2 and that Sohar, founded in 2023, keeps its name, products and customers. Sohar’s interfaces find a patient’s coverage from a name and date of birth, then check benefits, network status and a cost estimate across more than 1,000 payers. Named customers include BetterHelp, Headway, Rula and Talkiatry. The price was not disclosed. The so-what for practices is that the booking front door and the benefits check are now owned by one company, which should shorten the gap between “appointment booked” and “coverage confirmed.” Confidence: High on the facts in the release; Low on what it means for Sohar’s other customers, who now depend on a competitor-adjacent owner.

Carenet Health bought Orbita, an artificial intelligence (AI) platform that automates patient education and communication, its 11th acquisition. Per trade coverage of the announcement, a supplemental source because the company release was not reviewed, Orbita’s team joins Carenet immediately and its clients keep their platform and support teams. Orbita says it has delivered more than 50 million automated patient interactions to more than 1.5 million patients. Carenet says it expects to announce more deals in the coming weeks. Terms were not disclosed. For health systems, the pattern is consolidation of patient-access software into larger outsourced engagement vendors. Confidence: Medium; primary release not yet reviewed.

Elevance Health reports third-quarter results October 21, and the number to watch is whether its benefit expense ratio keeps climbing. In its second quarter 8-K, Elevance reported a benefit expense ratio of 89.7%, up 80 basis points from 88.9%, medical membership of about 44.9 million (down 1.5% year over year), and Medicaid membership of 8.36 million, down 4.3%. It guided to adjusted earnings of at least $27.00 per share for 2026 after recording a $935 million accrual in the first half tied to a February 27 CMS notice on historical Medicare Advantage risk adjustment data. UnitedHealth’s 88.4% on October 13 sets the comparison point. The date and time come from an aggregator reproducing the company’s October 5 notice, so treat the date as Medium confidence until checked against Elevance’s own page. Confidence: High on Q2 figures.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
Sohar Health	Zocdoc	Insurance eligibility software	Not disclosed (closed Oct 2, announced Oct 14)	Zocdoc release
Orbita	Carenet Health	AI patient communication	Not disclosed	Medical Buyer, supplemental
America’s Choice Healthplans, LLC	Comprehensive Healthcare Systems	Third-party benefits administrator	Not disclosed; cash “not material”; target revenue about $2.3 million in 2025	Stock Titan summary of the company release, supplemental